Background
Methods
Study patients and design
Treatment and clinical data collection
Radiographic assessments
Outcome assessments
Safety assessments
Statistical analysis
Results
Demographic characteristics of patients with RA at baseline
Parameters | CHB group (n = 32) | Non-CHB group (n = 128) | p valuea |
---|---|---|---|
Matched parameters | |||
Female, n (%) | 27 (84) | 108 (84) | 1.000 |
Age (years) | 49 (38–56) | 49 (38–57) | 0.964 |
DAS28-CRP | 4.6 (3.5–5.0) | 4.6 (3.8–5.3) | 0.791 |
Demographic characteristics | |||
Age of onset (years) | 44 (31–52) | 45 (33–53) | 0.948 |
Disease duration (months) | 36 (9–113) | 36 (12–84) | 0.805 |
Short duration (<6 months) | 3 (9) | 19 (15) | 0.476 |
Intermediate duration (6–24 months) | 12 (38) | 39 (30) | 0.501 |
Long duration (>24 months) | 17 (53) | 70 (55) | 0.887 |
Disease characteristics | |||
TJC28 | 6 (2–10) | 6 (3–10) | 0.914 |
SJC28 | 4 (1–8) | 4 (2–6) | 0.523 |
PainVAS | 4 (2–5) | 4 (3–6) | 0.131 |
PtGA | 5 (3–6) | 5 (3–6) | 0.355 |
PrGA | 5 (3–5) | 5 (3–6) | 0.276 |
HAQ | 0.6 (0–1.3) | 0.6(0.1–1.2) | 0.888 |
CRP (mg/L) | 12.1 (3.8–44.2) | 12.1 (4.8–32.0) | 0.543 |
ESR (mm/h) | 36 (20–62) | 50 (24–75) | 0.162 |
RF positivity, n (%) | 23 (72) | 96 (75) | 0.746 |
ACPA positivity, n (%) | 23 (72) | 101 (79) | 0.448 |
SDAI | 22.1 (13.6–31.3) | 21.2 (14.6–29.3) | 0.320 |
CDAI | 19 (12–28) | 20 (13–26) | 0.332 |
RAPID3 | 3.3 (2.1–4.6) | 3.6 (2.7–5.2) | 0.128 |
MMP-3 (ng/mL) | 184 (86–453) | 155 (86–358) | 0.440 |
Liver function | |||
AST (U/L) | 18 (14–25) | 16 (14–21) | 0.630 |
ALT (U/L) | 18 (12–29) | 15 (10–21) | 0.769 |
Radiographic status | |||
Bony erosions, n (%) | 25 (78) | 96 (75) | 0.742 |
JSN subscore | 5.5 (0–18.8) | 3.0 (1.0–9.8) | 0.078 |
JE subscore | 6.0 (1.0–22.0) | 4.0 (0.3–10.0) |
0.009
|
mTSS | 11.0 (1.3–36.3) | 8.0 (2.0–20.8) |
0.021
|
Previous medications, n (%) | |||
Treatment-naïveb | 11 (34) | 55 (43) | 0.431 |
GCs | 14 (44) | 48 (38) | 0.562 |
MTX | 16 (50) | 49 (38) | 0.283 |
LEF | 6 (19) | 34 (27) | 0.417 |
SSZ | 4 (13) | 1 (1) |
0.005
|
HCQ | 10 (31) | 12 (9) |
0.006
|
CysA | 1 (3) | 5 (4) | 0.853 |
Biologic agents | 1 (3) | 3 (2) | 0.821 |
Comparison of treatment after enrollment
Medication | CHB group (n = 32) | Non-CHB group (n = 128) | p valuea |
---|---|---|---|
Initial medications, n (%) | |||
GCs | 23 (72) | 89 (70) | 0.817 |
<5 mg/day | 1 (3) | 3 (2) | 0.821 |
≥5, ≤10 mg/day | 19 (59) | 81 (63) | 0.715 |
>10, ≤20 mg/day | 2 (6) | 4 (3) | 0.462 |
>20 mg/day | 1 (3) | 1 (1) | 0.357 |
MTX | 28 (87) | 121 (95) | 0.217 |
≤10 mg/week | 21 (66) | 79 (62) | 0.715 |
>10, ≤15 mg/week | 6 (19) | 40 (31) | 0.217 |
>15 mg/week | 1 (3) | 2 (2) | 0.606 |
LEF | 5 (16) | 107 (84) |
<0.001
|
SSZ | 14 (44) | 2 (2) |
<0.001
|
HCQ | 24 (75) | 14 (11) |
<0.001
|
CysA | 4 (13) | 4 (3) | 0.062 |
Iguratimod | 1 (3) | 10 (8) | 0.415 |
Biologic agents | 6 (19) | 38 (30) | 0.273 |
Tocilizumab | 4 (13) | 30 (23) | 0.234 |
Yi Sai Pu | 2 (6) | 5 (4) | 0.606 |
Infliximab | 0 (0) | 3 (2) | NA |
Six-month cumulative dose of medicationsb (mg) | |||
GCs | 900 (0–1406) | 1069 (0–1556) | 0.506 |
MTX | 260 (201–315) | 288 (260–348) |
0.024
|
LEF | 0 (0–0) | 1800 (1500–3263) |
<0.001
|
SSZ | 0 (0–270,000) | 0 (0–0) |
<0.001
|
HCQ | 54,000 (3000–72,000) | 0 (0–0) |
<0.001
|
CysAc | 0 (0–19,515) | 0 (0–4500) |
0.020
|
Iguratimodc | 0 (0–2625) | 0 (0–9000) | 0.330 |
Tocilizumabc | 0 (0–1880) | 0 (0–2400) | 0.218 |
Yi Sai Puc | 0 (0–600) | 0 (0–0) | 0.606 |
Infliximabc | 0 (0–0) | 0 (0–0) | NA |
One-year cumulative dose of medications (mg) | |||
GCs | 1800 (0–2790) | 1744 (0–2475) | 0.418 |
MTX | 520 (413–650) | 585 (520–715) |
0.023
|
LEF | 0 (0–0) | 3600 (2719–6600) |
<0.001
|
SSZ | 68,000 (0–536,000) | 0 (0–0) |
<0.001
|
HCQ | 90,000 (3000–144,000) | 0 (0–0) |
<0.001
|
CysAc | 0 (0–37,575) | 0 (0–12,825) |
0.016
|
Iguratimodc | 0 (0–5775) | 0 (0–9000) | 0.393 |
Tocilizumabc | 0 (0–1880) | 0 (0–2800) | 0.184 |
Yi Sai Puc | 0 (0–600) | 0 (0–0) | 0.606 |
Infliximabc | 0 (0–0) | 0 (0–0) | NA |
Patients with RA with CHB had more pronounced radiographic progression at month 12
Patients with RA with CHB achieved a lower level of clinical response
Risk factors for one-year radiographic progression and failure to achieve therapeutic target within 6 months
OR | 95% CI | p value* | |
---|---|---|---|
Univariate analyses | |||
Female | 0.845 | (0.373–1.915) | 0.687 |
Age | 0.993 | (0.969–1.018) | 0.598 |
Disease duration | 1.004 | (1.000–1.008) | 0.076 |
CHB status | 3.129 | (1.661–5.895) |
<0.001
|
TJC28 | 0.996 | (0.934–1.063) | 0.914 |
SJC28 | 0.982 | (0.908–1.062) | 0.651 |
Pain VAS | 1.056 | (0.905–1.232) | 0.491 |
PtGA | 1.094 | (0.939–1.274) | 0.248 |
PrGA | 1.086 | (0.921–1.281) | 0.326 |
HAQ | 1.346 | (0.990–1.830) | 0.058 |
CRP | 1.001 | (0.998–1.014) | 0.876 |
ESR | 0.999 | (0.989–1.008) | 0.786 |
RF positivity | 2.355 | (0.921–6.023) | 0.074 |
ACPA positivity | 1.983 | (0.775–5.070) | 0.153 |
DAS28-CRP | 1.011 | (0.742–1.378) | 0.944 |
MMP-3 | 1.001 | (0.999–1.002) | 0.292 |
mTSS | 1.016 | (1.006–1.026) |
0.001
|
Treatment-naïveb | 0.710 | (0.365–1.381) | 0.313 |
GCs | 2.300 | (0.964–5.489) | 0.061 |
MTX | 1.369 | (0.330–5.678) | 0.666 |
LEF | 0.684 | (0.359–1.304) | 0.248 |
SSZ | 1.984 | (0.876–4.495) | 0.101 |
HCQ | 1.611 | (0.828–3.135) | 0.160 |
CysA | 1.591 | (0.490–5.167) | 0.440 |
Iguratimod | 1.130 | (0.348–3.670) | 0.839 |
Biologic agents | 0.477 | (0.200–1.139) | 0.095 |
MTX combined with SSZ and HCQ | 2.265 | (0.949–5.406) | 0.066 |
MTX combined with LEF | 0.719 | (0.384–1.346) | 0.302 |
One-year cumulative dose of GCsc | 1.000 | (1.000–1.000) |
0.010
|
One-year cumulative dose of MTX | 0.999 | (0.998–1.000) | 0.224 |
One-year cumulative dose of LEFd | 1.000 | (1.000–1.000) | 0.074 |
One-year cumulative dose of SSZ | 1.001 | (1.000–1.003) | 0.133 |
One-year cumulative dose of HCQ | 1.004 | (0.998–1.009) | 0.160 |
One-year cumulative dose of CysAe | 1.000 | (1.000–1.000) | 0.124 |
One-year cumulative dose of iguratimodf | 1.000 | (1.000–1.000) | 0.761 |
One-year cumulative dose of tocilizumabg | 1.000 | (0.999–1.000) | 0.232 |
One-year cumulative dose of Yi Sai Pu | 1.000 | (0.998–1.003) | 0.817 |
One-year cumulative dose of infliximab | 0.997 | (0.989–1.006) | 0.564 |
Bivariate models | |||
CHB status adjusted for baseline mTSS | 2.610 | (1.338–5.092) |
0.005
|
CHB status adjusted for one-year cumulative dose of GCs | 2.881 | (1.511–5.493) |
0.001
|
Multivariate model | |||
CHB status adjusted for baseline mTSS and one-year cumulative dose of GCs | 2.403 | (1.218–4.743) |
0.011
|
OR | 95% CI | p valuea | |
---|---|---|---|
Univariate analyses | |||
Female | 1.235 | (0.367–4.155) | 0.734 |
Age | 1.012 | (0.979–1.045) | 0.488 |
Disease duration | 1.000 | (0.994–1.007) | 0.969 |
CHB status | 3.077 | (1.349–7.017) |
0.008
|
TJC28 | 1.059 | 0.986–1.137 | 0.115 |
SJC28 | 1.035 | 0.951–1.127 | 0.421 |
Pain VAS | 1.096 | 0.897–1.338 | 0.369 |
PtGA | 1.192 | 0.977–1.455 | 0.083 |
PrGA | 1.142 | 0.920–1.418 | 0.230 |
HAQ | 1.318 | 0.880–1.975 | 0.180 |
CRP | 1.004 | (0.988–1.020) | 0.616 |
ESR | 1.000 | (0.987–1.021) | 0.949 |
RF positivity | 1.637 | (0.557–4.811) | 0.371 |
ACPA positivity | 0.452 | (0.195–1.043) | 0.063 |
DAS28-CRP | 1.394 | (0.936–2.077) | 0.102 |
MMP-3 | 1.000 | (0.999–1.002) | 0.751 |
mTSS | 1.010 | (0.995–1.024) | 0.195 |
Treatment-naïveb | 0.300 | (0.102–0.881) |
0.029
|
GCs | 1.178 | (0.465–2.989) | 0.729 |
MTX | 0.266 | (0.099–0.716) |
0.009
|
LEF | 0.468 | (0.206–1.060) | 0.069 |
SSZ | 1.350 | (0.401–4.543) | 0.628 |
HCQ | 2.064 | (0.893–4.768) | 0.090 |
CysA | 2.850 | (0.847–9.591) | 0.091 |
Iguratimod | 2.032 | (0.604–6.837) | 0.252 |
Biologic agents | 0.555 | (0.189–1.631) | 0.285 |
MTX combined with SSZ and HCQ | 1.175 | (0.275–5.009) | 0.828 |
MTX combined with LEF | 0.365 | (0.155–0.861) |
0.021
|
Six-month cumulative dose of GCsc | 1.000 | (1.000–1.001) | 0.340 |
Six-month cumulative dose of MTX | 0.997 | (0.993–1.000) |
0.049
|
Six-month cumulative dose of LEFd | 1.000 | (0.999–1.000) | 0.113 |
Six-month cumulative dose of SSZ | 1.000 | (0.995–1.005) | 0.890 |
Six-month cumulative dose of HCQ | 1.008 | (0.994–1.022) | 0.245 |
Six-month cumulative dose of CysAe | 1.000 | (1.000–1.000) |
0.023
|
Six-month cumulative dose of iguratimodf | 1.000 | (1.000–1.000) | 0.259 |
Six-month cumulative dose of tocilizumabg | 1.000 | (0.999–1.000) | 0.337 |
Six-month cumulative dose of Yi Sai Pu | 1.001 | (0.999–1.004) | 0.322 |
Six-month cumulative dose of infliximab | 0.997 | (0.986–1.009) | 0.659 |
Bivariate models | |||
CHB status adjusted for treatment-naïve status | 2.844 | (1.245–6.498) |
0.013
|
CHB status adjusted for MTX | 2.722 | (1.177–6.298) |
0.019
|
CHB status adjusted for the regimen of MTX combined with LEF | 3.077 | (1.349–7.017) |
0.008
|
CHB status adjusted for 6-month cumulative dose of MTX | 3.077 | (1.349–7.017) |
0.008
|
CHB status adjusted for 6-month cumulative dose of CysA | 3.077 | (1.349–7.017) |
0.008
|
Multivariate models | |||
CHB status adjusted for treatment-naïve status, MTX therapy, the regimen of MTX combined with LEF, and 6-month cumulative dose of CysA | 2.617 | (1.140–6.007) |
0.023
|
CHB status adjusted for treatment-naïve status, 6-month cumulative dose of MTX, the regimen of MTX combined with LEF, and 6-month cumulative dose of CysA | 2.844 | (1.245–6.498) |
0.013
|
Safety
Side effect | CHB group (n = 32) | Non-CHB group (n = 128) | p valuea |
---|---|---|---|
Total side effects, n (%) | 15 (47) | 68 (53) | 0.572 |
Infections | 5 (16) | 16 (13) | 0.676 |
Gastrointestinal discomfort | 7 (22) | 22 (17) | 0.583 |
Trichomadesis | 2 (6) | 13 (10) | 0.547 |
Neutropenia | 2 (6) | 14 (11) | 0.484 |
Aminotransferase elevation | 6 (19) | 39 (30) | 0.244 |
< two fold ULN | 4 (13) | 30 (23) | 0.234 |
≥ two fold, < three fold ULN | 1 (3) | 7 (6) | 0.630 |
≥ three fold ULN | 1 (3) | 2 (2) | 0.606 |
Antiviral prophylaxis | 14 (44) | 0 (0) | NA |
HBV reactivation | 11 (34) | 0 (0) | NA |
Antiviral prophylaxis (+) | 3 (9) | 0 (0) | NA |
Antiviral prophylaxis (−) | 8 (25) | 0 (0) | NA |